<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03530631</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300000343</org_study_id>
    <nct_id>NCT03530631</nct_id>
  </id_info>
  <brief_title>Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance</brief_title>
  <official_title>Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this balanced-placebo design study is to pilot a larger study to further
      explore the current evidence that stimulant medications are not cognitive enhancers, despite
      this rampant belief in young adults. While the lack of cognitive enhancement from stimulant
      medication has been documented in prior research, this study is the first to utilize
      neuroimaging technology to examine brain regions activated during neurocognitive tasks when
      participants believe they have been administered stimulant medication or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2 X 2 within subjects, balanced placebo design and all participants will experience
      each of the four conditions during four sequential weeks. Medication administered (Adderall
      vs. placebo) is crossed with instructional set (truth vs. deception) and participants'
      performance on neurocognitive tasks is compared across these groups. For example,
      participants are either given stimulant medication or placebo, and are either accurately told
      or inaccurately told that they received stimulant medication or placebo. Neuroimaging is
      being utilized to investigate whether participants' expectations regarding the benefits of
      stimulant medication affects their performance on neurocognitive tasks. The hypothesis of the
      study is that participants' expectations regarding stimulant medication will affect their
      performance on neurocognitive tasks, rather than the actual effect of the medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2018</start_date>
  <completion_date type="Actual">December 18, 2018</completion_date>
  <primary_completion_date type="Actual">December 18, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2 X 2, within-subjects, balanced placebo design</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions</measure>
    <time_frame>A total of 4 imagining sessions, an average of 60 minutes each</time_frame>
    <description>Using a balanced placebo design, participants were either administered mixed amphetamine salts or placebo. Their cognitive performance was assessed in the MRI scanner. The main outcome measure was the feasibility of participants attending four neuroimaging sessions.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Expectancy Versus Pharmacotherapy Effect of Adderall</condition>
  <arm_group>
    <arm_group_label>Adderall/Truth</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be told they are receiving Adderall and will actually be administered Adderall.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Truth</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be told they are receiving placebo and will actually be administered placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall/Deception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be told they are receiving Adderall and will actually be administered placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Deception</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be told they are receiving placebo and will actually be administered Adderall.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall</intervention_name>
    <description>Participants will be administered Adderall</description>
    <arm_group_label>Adderall/Truth</arm_group_label>
    <arm_group_label>Placebo/Deception</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be administered placebo</description>
    <arm_group_label>Adderall/Deception</arm_group_label>
    <arm_group_label>Placebo/Truth</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age (18-24)

          -  College student with at least average IQ

          -  Willingness to standardize caffeine intake to 100 mg on day of study

        Exclusion Criteria:

          -  Attention Deficit/Hyperactivity Disorder (ADHD)

          -  First degree relative with ADHD

          -  Unwillingness to comply with caffeine specifications

          -  Regular use of Adderall

          -  Pregnant/breastfeeding

          -  History of substance use disorders

          -  Illicit stimulant use within the last year

          -  Contraindications to stimulants (i.e., tics, Tourette's, cardiac disease,
             hypertension)

          -  Uncontrolled medical illness

          -  Active contagious infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Cropsey, Psy.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2018</study_first_posted>
  <results_first_submitted>July 29, 2019</results_first_submitted>
  <results_first_submitted_qc>September 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2019</results_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Karen Cropsey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03530631/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Only four subjects were recruited for this pilot study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adderall Within Subjects Design</title>
          <description>This is a within-subjects design in which participants will complete all four periods/conditions. For two sessions, participants will be accurately told that they are receiving Adderall or placebo, respectively. For two sessions, participants will be inaccurately informed that they are receiving Adderall or placebo. The participants will be counterbalanced across conditions to control for order effects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Adderall/Truth</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Placebo/Truth</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Adderall/Deception</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Placebo/Deception</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adderall Within Subjects Design</title>
          <description>This is a within-subjects design in which participants will complete all four periods/conditions. For two sessions, participants will be accurately told that they are receiving Adderall or placebo, respectively. For two sessions, participants will be inaccurately informed that they are receiving Adderall or placebo. The participants will be counterbalanced across conditions to control for order effects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions</title>
        <description>Using a balanced placebo design, participants were either administered mixed amphetamine salts or placebo. Their cognitive performance was assessed in the MRI scanner. The main outcome measure was the feasibility of participants attending four neuroimaging sessions.</description>
        <time_frame>A total of 4 imagining sessions, an average of 60 minutes each</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adderall/Truth</title>
            <description>Participants will be told they are receiving Adderall and will actually be administered Adderall.
Adderall: Participants will be administered Adderall</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Truth</title>
            <description>Participants will be told they are receiving placebo and will actually be administered placebo.
Placebo: Participants will be administered placebo</description>
          </group>
          <group group_id="O3">
            <title>Adderall/Deception</title>
            <description>Participants will be told they are receiving Adderall and will actually be administered placebo.
Placebo: Participants will be administered placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Deception</title>
            <description>Participants will be told they are receiving placebo and will actually be administered Adderall.
Adderall: Participants will be administered Adderall</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions</title>
          <description>Using a balanced placebo design, participants were either administered mixed amphetamine salts or placebo. Their cognitive performance was assessed in the MRI scanner. The main outcome measure was the feasibility of participants attending four neuroimaging sessions.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to one month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adderall/Truth</title>
          <description>Participants will be told they are receiving Adderall and will actually be administered Adderall.
Adderall: Participants will be administered Adderall</description>
        </group>
        <group group_id="E2">
          <title>Placebo/Truth</title>
          <description>Participants will be told they are receiving placebo and will actually be administered placebo.
Placebo: Participants will be administered placebo</description>
        </group>
        <group group_id="E3">
          <title>Adderall/Deception</title>
          <description>Participants will be told they are receiving Adderall and will actually be administered placebo.
Placebo: Participants will be administered placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo/Deception</title>
          <description>Participants will be told they are receiving placebo and will actually be administered Adderall.
Adderall: Participants will be administered Adderall</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Cropsey</name_or_title>
      <organization>University of Alabama, Birmingham</organization>
      <phone>(205) 975-7809</phone>
      <email>kcropsey@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

